Twitter Feeds of Interest
Announcements
- Dr. Guzman's laboratory awarded Leukemia & Lymphoma Society Translational Research Program grant to target leukemia stems in their protected niche using nanotechnology. LLS press release | Official Weill Cornell Announcement.
- Collaborating with scientists at Weill Cornell and MSKCC, we help elucidate the Hsp90 interactome in AML and demonstrate a means of predicting which patients will be sensitive to Hsp90 inhibitor therapy. Hsp90 is an important mediator of oncogene addiction. See the report in Nature Chemical Biology.
- Read our most recent invited review on the current state of therapeutics against leukemia stem cells.
- We demonstrate that fluorescent conjugates of PU-H71 can monitor Hsp90 in heterogeneous AML cell populations. [subscription required]
- PI-3 kinase and mTOR inhibitors synergize with parthenolide, leading to more effective eradication of leukemia stem cells in AML.
- V Foundation awards Dr. Guzman its Scholar Award.
- Dr. Guzman awarded $1.5M NIH Director's New Innovator Award.
- Dr. Guzman co-authors the review, Leukemia Stem Cells: Seek and Destroy, with Dr. Gail Roboz. [subscription required]
- Updated August 2012.